Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sintx Technologies (SINT) Long-Term Debt Issuances (2014 - 2021)

Sintx Technologies' quarterly Long-Term Debt Issuances came in at -$1000.0 in Q4 2021, down 100.2% quarter-over-quarter from $510000.0 in Q1 2021.

Sintx Technologies has reported Long-Term Debt Issuances for 3 years, with the latest figure at -$1000.0 in Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to -$1000.0; the trailing twelve-month figure through Dec 2021 stood at $509000.0 (changed N/A YoY), and the FY2021 full-year result was $509000.0, up 25.37% from the prior year.
  • Long-Term Debt Issuances for Q4 2021 stood at -$1000.0, down from $510000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $705000.0 in Q1 2018, with the low at -$1000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Sintx Technologies 8.71 Mn 6.82 Mn 144,000.00 -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 -1,000.00
Dec 31, 2021 -1,000.00
Mar 31, 2021 510,000.00
Mar 31, 2021 510,000.00
Mar 31, 2018 705,000.00
Mar 31, 2018 705,000.00
Dec 31, 2014 1.00 Mn
Dec 31, 2014 1.00 Mn
Sep 30, 2014 3.50 Mn
Sep 30, 2014 3.50 Mn